Skip to main content
Vcanbio Cell & Gene Engineering Corp., Ltd logo

Vcanbio Cell & Gene Engineering Corp., Ltd — Investor Relations & Filings

Ticker · 600645 ISIN · CNE000000545 LEI · 300300FLWFDJPQYVAZ24 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,580 across all filing types
Latest filing 2022-08-22 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 600645

About Vcanbio Cell & Gene Engineering Corp., Ltd

https://www.vcanbio.com/

Vcanbio Cell & Gene Engineering Corp., Ltd. specializes in the fields of cell therapy, gene technology, and precision medicine. The company operates a comprehensive business model centered on the storage of hematopoietic and mesenchymal stem cells, providing long-term bio-banking services for cord blood and other biological tissues. Its technical portfolio includes advanced genetic testing services, such as prenatal screening and oncology diagnostics, alongside the development of cell-based therapeutic products. Vcanbio maintains a network of specialized laboratories and storage facilities to support clinical research and personalized healthcare applications. The organization focuses on translating biotechnological advancements into clinical solutions, emphasizing quality control in cell processing and genomic analysis to serve the evolving needs of the regenerative medicine and diagnostic sectors.

Recent filings

Filing Released Lang Actions
中源协和细胞基因工程股份有限公司2022年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions from an extraordinary shareholders' meeting held on August 22, 2022. It details the meeting attendance, voting results on specific proposals such as changing the registered address and business scope, and changing the accounting firm. It includes legal witness statements confirming the legality of the meeting and voting process. The document is not a full report but a formal announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1857 characters), consistent with an announcement rather than a full report.
2022-08-22 Chinese
北京国枫律师事务所关于中源协和细胞基因工程股份有限公司2022年第三次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, attendance, and voting procedures of a company's 2022 third extraordinary general meeting of shareholders. It details the legality and validity of the meeting's call, attendance, and voting results, including approval of specific proposals. The document does not contain financial statements or detailed financial performance data, nor is it a transcript or presentation. It is a formal legal opinion related to the shareholder meeting and voting results. This type of document aligns best with Declaration of Voting Results & Voting Rights Announcements (DVA), as it reports official voting results and validates the meeting procedures and outcomes.
2022-08-22 Chinese
中源协和细胞基因工程股份有限公司关于召开2022年第三次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2022 third extraordinary general meeting of shareholders for the company 中源协和细胞基因工程股份有限公司. It includes information about the meeting date, voting methods, agenda items, registration procedures, and proxy authorization. There is no financial data or report content, but rather a notice and instructions related to the shareholder meeting. The document length is 3157 characters, which is relatively short and consistent with an announcement rather than a full report. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2022-08-16 Chinese
中源协和细胞基因工程股份有限公司2022年第三次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2022 Third Extraordinary General Meeting of Shareholders" of Zhongyuan Xiehe Cell Gene Engineering Co., Ltd. It includes the meeting agenda, voting procedures, and detailed proposals for shareholder approval. The proposals include changes to the company's registered address and business scope, amendments to the Articles of Association, and the appointment of a new accounting firm for the 2022 audit. The document is a set of meeting materials prepared for the shareholders to review and vote on during the extraordinary general meeting. It is not a report like an annual or interim report, nor is it a transcript or earnings release. It is not a voting results announcement but the materials provided before or during the meeting. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual or Extraordinary General Meeting.
2022-08-12 Chinese
中源协和细胞基因工程股份有限公司关于召开2022年第三次临时股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about convening the 2022 third extraordinary general meeting of shareholders for a company, detailing the meeting date, voting methods, agenda items, and procedural instructions. It includes information about the meeting logistics, voting system, and proxy authorization form. There is no financial data, earnings information, or detailed report content. The document is an announcement of a shareholder meeting rather than the meeting materials or results themselves. Therefore, it fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings.
2022-08-05 Chinese
中源协和细胞基因工程股份有限公司独立董事关于变更会计师事务所的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the pre-approval of changing the company's accounting firm for the 2022 audit. It references a board meeting to approve the change of the auditor. The document is short (554 characters) and does not contain any financial statements or detailed audit results. It is not an audit report itself but an announcement related to governance and audit firm change approval. This fits best under Board/Management Information (MANG) as it concerns a board decision on management of audit services, rather than a full audit report or annual report.
2022-08-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.